Connect Biopharma Holdings LTD (CNTB) — SEC Filings

Overview

Connect Biopharma Holdings LTD (CNTB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 23, 2026: Connect Biopharma Holdings Ltd filed an 8-K on April 23, 2026, primarily for Regulation FD Disclosure, Other Events, and Financial Statements/Exhibits. The filing includes an exhibit (EX-99.1) related to a 'seabreeze interi' document, though specific details of this exhibit are not provided in the f

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 24 neutral. The dominant filing sentiment for Connect Biopharma Holdings LTD is neutral.

Filing Type Overview

Connect Biopharma Holdings LTD (CNTB) has filed 11 8-K, 3 10-Q, 1 10-K, 7 6-K, 3 SC 13D/A, 1 20-F, 1 SC 13D, 2 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• Connect Biopharma Files 8-K with Exhibits — 8-K · Apr 23, 2026 Risk: low
  Connect Biopharma Holdings Ltd filed an 8-K on April 23, 2026, primarily for Regulation FD Disclosure, Other Events, and Financial Statements/Exhibits. The fili
• Connect Biopharma Files 8-K on Agreements and Equity Sales — 8-K · Mar 30, 2026 Risk: medium
  Connect Biopharma Holdings Ltd. filed an 8-K on March 30, 2026, disclosing the entry into a material definitive agreement and unregistered sales of equity secur
• 8-K Filing — 8-K · Dec 23, 2025
• Connect Biopharma's Net Loss Soars Amid Revenue Collapse — 10-Q · Nov 12, 2025 Risk: high
  Connect Biopharma Holdings Ltd (CNTB) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $40.371 million, a subs
• Connect Biopharma Files 8-K for Regulation FD Disclosure — 8-K · Sep 16, 2025 Risk: low
  Connect Biopharma Holdings Ltd. filed an 8-K on September 16, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures
• Connect Biopharma Swings to Loss Amid Revenue Collapse — 10-Q · Aug 13, 2025 Risk: high
  Connect Biopharma Holdings Ltd (CNTB) reported a significant net loss of $23.171 million for the six months ended June 30, 2025, a stark contrast to the net inc
• Connect Biopharma Holdings Ltd. Announces Board and Officer Changes — 8-K · Jul 22, 2025 Risk: medium
  Connect Biopharma Holdings Ltd. announced on July 22, 2025, changes in its board and officer appointments, including the departure of directors and the election
• Connect Biopharma Terminates Material Definitive Agreement — 8-K · Jul 21, 2025 Risk: medium
  Connect Biopharma Holdings Ltd. announced on July 18, 2025, the termination of a material definitive agreement. The company, incorporated in the Cayman Islands,
• J&J Acquires Connect Biopharma for $1B — 8-K · Jul 17, 2025 Risk: medium
  Connect Biopharma Holdings Ltd. announced on July 16, 2025, that it has entered into a definitive agreement to be acquired by Johnson & Johnson for approximatel
• Connect Biopharma Files 8-K — 8-K · Jul 9, 2025 Risk: low
  Connect Biopharma Holdings Ltd. filed an 8-K on July 9, 2025, reporting on various events. The filing indicates the company's principal executive offices are lo
• Connect Biopharma Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Connect Biopharma Holdings Ltd filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, incl
• J&J Acquires Connect Biopharma for $1B — 8-K · May 14, 2025 Risk: medium
  Connect Biopharma Holdings Ltd. announced on May 14, 2025, that it has entered into a definitive agreement to be acquired by Johnson & Johnson for approximately
• Connect Biopharma Files 8-K — 8-K · May 13, 2025 Risk: medium
  Connect Biopharma Holdings Ltd. filed an 8-K on May 13, 2025, to report on other events and a Regulation FD disclosure. The filing does not contain specific det
• Connect Biopharma Files 8-K with Regulatory Updates — 8-K · Apr 1, 2025 Risk: low
  Connect Biopharma Holdings Ltd. filed an 8-K on April 1, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures
• 10-K Filing — 10-K · Mar 31, 2025
• Connect Biopharma Files March 2025 6-K Report — 6-K · Mar 28, 2025 Risk: low
  Connect Biopharma Holdings Ltd. filed a Form 6-K on March 28, 2025, reporting information for the month of March 2025. The company is a foreign private issuer a
• Connect Biopharma Files 6-K Report — 6-K · Dec 23, 2024 Risk: low
  Connect Biopharma Holdings Limited filed a Form 6-K on December 23, 2024, reporting for the month of December 2024. The filing is a report of a foreign private
• Connect Biopharma Files 6-K for September 2024 — 6-K · Sep 6, 2024 Risk: low
  Connect Biopharma Holdings Limited filed a Form 6-K on September 6, 2024, to report its activities for the month of September 2024. The filing indicates that th
• Connect Biopharma Files 6-K with Mid-Year Financials — 6-K · Sep 5, 2024 Risk: low
  Connect Biopharma Holdings Ltd filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the six months ended June 30, 2024
• Connect Biopharma Files 6-K, Reports Foreign Issuer Status — 6-K · Aug 2, 2024 Risk: low
  Connect Biopharma Holdings Limited filed a Form 6-K on August 2, 2024, reporting its status as a foreign private issuer. The filing indicates the company is sub
• Connect Biopharma Ownership Update — SC 13D/A · Jul 1, 2024 Risk: medium
  On July 1, 2024, James Huang and Panacea Venture Healthcare Fund II, L.P. filed an amendment (No. 2) to their Schedule 13D regarding Connect Biopharma Holdings
• Connect Biopharma Files June 2024 6-K Report — 6-K · Jun 12, 2024 Risk: low
  Connect Biopharma Holdings Limited filed a Form 6-K on June 12, 2024, reporting its activities for the month of June 2024. The company, incorporated in E9 with
• Connect Biopharma Holdings Ltd Files 20-F for Fiscal Year 2023 — 20-F · Apr 16, 2024 Risk: low
  Connect Biopharma Holdings Ltd (CNTB) filed a Foreign Annual Report (20-F) with the SEC on April 16, 2024. Connect Biopharma Holdings Ltd filed its annual repor
• Panacea Venture Group Amends Connect Biopharma 13D Filing — SC 13D/A · Feb 27, 2024 Risk: medium
  Panacea Innovation Ltd, along with group members James Huang, Panacea Venture Healthcare Fund II GP Co Ltd., and Panacea Venture Healthcare Fund II L.P., filed
• RA Capital Amends Connect Biopharma Stake (Amendment No. 5) — SC 13D/A · Feb 27, 2024 Risk: medium
  RA Capital Management, L.P. filed an SC 13D/A Amendment No. 5 on February 27, 2024, regarding its beneficial ownership in Connect Biopharma Holdings Ltd. The fi
• Panacea Venture Group Files SC 13D on Connect Biopharma Holdings — SC 13D · Feb 13, 2024 Risk: low
  Panacea Innovation Ltd, along with group members James Huang, Panacea Venture Healthcare Fund II GP Company, LTD., and Panacea Venture Healthcare Fund II, L.P.,
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Connect Biopharma Appoints Biotech Veteran James Huang to Board — 6-K · Feb 12, 2024 Risk: low
  Connect Biopharma Holdings Limited announced on February 12, 2024, the immediate appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors. Mr. Hu

Risk Profile

Risk Assessment: Of CNTB's 25 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Connect Biopharma Holdings LTD's most recent 10-Q filing (Nov 12, 2025):

• Revenue: $64K
• Net Income: -$40.371M
• EPS: -$0.73
• Debt-to-Equity: 0.22
• Cash Position: $37.845M
• Operating Margin: -100.1%
• Total Assets: $67.361M
• Total Debt: $11.990M

Key Executives

• James Huang
• Peter Kolchinsky
• James Zuie-chin Huang

Industry Context

Connect Biopharma operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on developing novel therapeutics for immune-disrupting diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and successful commercialization, often facing competition from both large pharmaceutical companies and smaller, agile biotech firms.

Top Tags

disclosure (5) · biotech (4) · reporting (4) · foreign-private-issuer (4) · biopharma (3) · sec-filing (3) · regulation-fd (2) · Clinical Stage (2) · Net Loss (2) · Revenue Decline (2)

Key Numbers

• Net Loss (9 months): $40.371M — Increased from $6.722M in 2024, a 500% rise.
• License & Collaboration Revenue (9 months): $64K — Plummeted from $25.335M in 2024, a 99.7% decrease.
• Cash & Cash Equivalents: $37.845M — Decreased from $78.232M at Dec 31, 2024, a 51.7% drop.
• Research & Development Expense (9 months): $26.516M — Increased from $23.020M in 2024, a 15.2% rise.
• General & Administrative Expense (9 months): $16.096M — Increased from $15.148M in 2024, a 6.3% rise.
• Total Cash, Cash Equivalents, and Short-term Investments: $54.8M — Management believes this is sufficient for at least one year.
• Total Assets: $67.361M — Decreased from $101.284M at Dec 31, 2024.
• Total Liabilities: $11.990M — Increased from $9.118M at Dec 31, 2024.
• Ordinary Shares Outstanding: 55,903,513 — As of October 31, 2025.
• Basic and Diluted Net Loss Per Share (9 months): $(0.73) — Increased from $(0.12) in 2024.
• Net Loss: $23.171M — for the six months ended June 30, 2025, compared to $6.154M net income in H1 2024
• License and Collaboration Revenue: $48K — for the six months ended June 30, 2025, down from $24.116M in H1 2024
• Research and Development Expense: $15.406M — for the six months ended June 30, 2025, up from $14.011M in H1 2024
• Cash and Cash Equivalents: $40.632M — as of June 30, 2025, down from $78.232M at December 31, 2024
• Net Cash Used in Operating Activities: $22.550M — for the six months ended June 30, 2025

Forward-Looking Statements

• {"claim":"Connect Biopharma will see increased strategic investment activity.","entity":"Connect Biopharma Holdings Limited","targetDate":"2025-02-12","confidence":"medium"}
• {"claim":"The company's focus on innovative life science projects will strengthen.","entity":"Connect Biopharma Holdings Limited","targetDate":"2025-02-12","confidence":"medium"}

Related Companies

JNJ

Frequently Asked Questions